Ardena To Attend CPHI Worldwide Milan 2026, Launching Charity Step Challenge "From Molecules To Miles"

GHENT, Belgium — Ardena, a full-service contract development and manufacturing organization (CDMO) supporting pharmaceutical companies from molecule to market, will participate in CPHI Worldwide, taking place October 6 –8, 2026, in Milan, Italy. The company will welcome visitors at Booth 10F1 with a dedicated team ready to discuss development and manufacturing solutions across the drug product lifecycle.

A Key Meeting Point for the Pharma and Biotech Industry

CPHI Worldwide is one of the pharmaceutical industry's largest global gatherings, bringing together manufacturers, suppliers, and service providers to discuss innovation, regulatory trends, and emerging opportunities across the drug development value chain . Ardena's presence at the event underlines the company's commitment to fostering long -term partnerships and enabling productive, value-driven conversations with clients and industry stakeholders throughout the three-day event.

Expert Team On-Site

Attendees will have the opportunity to meet with Ardena specialists covering a range of disciplines relevant to pharmaceutical development and manufacturing, including:

• Jeremie Trochu, Chief Executive Officer — 20 years of experience building and scaling life sciences and CDMO businesses globally
• Henny Zijlstra, Chief Commercial Officer — senior commercial leadership across the pharmaceutical and CDMO sector, including at Lonza and Adragos
• Ben Ash, Chief Financial Officer — over 20 years of finance leadership in the pharmaceutical industry, including CFO roles at Essential Pharma, PTC Therapeutics, and Shire
• Raja Yekkala, PhD, Business Development Director  — 20+ years across CMC development, analytical sciences, drug product development, and clinical supply
• Thomas Scullion, PhD, VP, Business Development, Bioanalytical Sciences — expertise in regulatory bioanalysis, translational biomarkers, and biologics/cell and gene therapy support
• Marion Andrist, Business Development Director — 10+ years across pharma, biotech, and CDMO/CRO industries in Europe, with a focus on drug substance and drug product
• Juan Jose Serrano, Business Development Manager — international business development, market analysis, and strategic account growth
• Javier Gurrea, PhD, Formulation Development Group Leader — nearly 10 years of experience in spray drying and GMP drug product development.
• Laure Descamps, PhD, Senior Formulation Scientist — solid dosage development and process understanding, supporting early -phase formulation strategies for complex molecules
• Bastiaan Buddingh, Principal Scientist / Business Development Director, Nanomedicines — expertise in nanomedicine, business development and complex nanoparticle-based programs.

Charity Initiative: "From Molecules to Miles"

In addition to its business activities, Ardena will run a charity initiative throughout the event, “From Molecules to Miles.” Visitors to the Ardena booth can pick up a step tracker watch and join a daily step-count challenge. Each day, the participant wit h the highest recorded step count will be selected as the winner, and Ardena will make a donation to Pink Ribbon in recognition of their achievement. Each winner will also receive an official certificate acknowledging their participation and contribution to the initiative.

The initiative reflects Ardena's broader commitment to social responsibility, translating a simple, engaging activity on the show floor into tangible support for a good cause.

Visit Ardena at CPHI Worldwide 2026

Ardena invites all CPHI attendees to visit Booth 10F1 to learn more about its integrated CDMO services, meet the team, and join the "From Molecules to Miles" challenge.

Event details:

• Event: CPHI Worldwide 2026
• Dates: October 6 –8, 2026
• Location: Fiera Milano, Milan, Italy
• Booth: 10F1

About Ardena

Ardena is an integrated contract development and manufacturing organization (CDMO) and bioanalytical CRO, supporting pharmaceutical and biotech companies from molecule to market. Its services span drug substance and drug product development, nanomedicine, bioanalysis, and CMC regulatory support, including complex and high -potency molecules that few CDMOs are equipped to handle. Ardena operates across five sites in Belgi um, the Netherlands, Spain, and the United States: Ghent (Belgium), Oss and Assen (Netherlands), Pamplona (Spain), and Somerset (USA).